AMRN Amarin Corp Plc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AMRN

Price (delayed)

$16.37

Market cap

$340.56M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.6

Enterprise value

$214.88M

?
Relative Growth: Rel. Growth: 14
Relative Strength: Rel. Strength: 47
Relative Valuation: Rel. Valuation: 24
Relative Profitability: Rel. Profitability: 40

Amarin is a rapidly growing, innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From its scientific research foundation to its focus on clinical trials, and now its ...

Highlights
The company's EPS has surged by 64% YoY and by 11% QoQ
AMRN's net income has soared by 62% YoY and by 13% from the previous quarter
Amarin's gross profit has surged by 52% YoY but it has decreased by 6% QoQ
AMRN's gross margin has surged by 51% year-on-year but it is down by 7% since the previous quarter
The equity has declined by 5% year-on-year and by 2.1% since the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: http://www.amarincorp.com
Peers: ABBV ALKS TEVA AZN

Key stats

What are the main financial stats of AMRN

AMRN stock price

How has the Amarin stock price performed over time
Intraday
-0.61%
1 week
0.12%
1 month
13.13%
1 year
-1.68%
YTD
17.31%
QTD
2.7%

Financial performance

How have Amarin's revenue and profit performed over time
Revenue
$216.76M
Gross profit
$113.51M
Operating income
-$44.75M
Net income
-$33.61M
Gross margin
52.4%
Net margin
-15.5%
AMRN's net margin has surged by 62% year-on-year and by 15% since the previous quarter
AMRN's net income has soared by 62% YoY and by 13% from the previous quarter
AMRN's operating margin has surged by 54% year-on-year and by 12% since the previous quarter
AMRN's operating income has soared by 53% year-on-year and by 11% since the previous quarter

Price vs fundamentals

How does AMRN's price correlate with its fundamentals

Growth

What is Amarin's growth rate over time

Valuation

What is Amarin stock price valuation
P/E
N/A
P/B
0.76
P/S
1.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.99
The company's EPS has surged by 64% YoY and by 11% QoQ
AMRN's P/B is 24% below its 5-year quarterly average of 1.0 but 9% above its last 4 quarters average of 0.7
The equity has declined by 5% year-on-year and by 2.1% since the previous quarter
The P/S is 13% more than the last 4 quarters average of 1.4 and 5% more than the 5-year quarterly average of 1.5

Efficiency

How efficient is Amarin business performance
The company's return on sales has surged by 63% YoY and by 16% QoQ
The ROIC has soared by 59% YoY and by 12% QoQ
Amarin's ROA has soared by 58% YoY and by 12% from the previous quarter
AMRN's ROE has soared by 58% YoY and by 13% from the previous quarter

Dividends

What is AMRN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AMRN.

Financial health

How did Amarin financials performed over time
AMRN's total liabilities is up by 8% year-on-year but it is down by 7% since the previous quarter
AMRN's quick ratio is up by 5% since the previous quarter but it is down by 2.9% year-on-year
AMRN's debt is 99% smaller than its equity
Amarin's debt to equity has plunged by 50% YoY
AMRN's debt is down by 30% year-on-year and by 8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.